Last updated: 2026-09-05 02:03:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Biogen Inc. (BIIB) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $220,88, with a market capitalization of $32,90B and a P/E ratio of 39,75. Over the past 52 weeks, its price has ranged from $135,39 to $225,80. This page covers its latest market performance, valuation, price trends and company information.
$32,90B | |
$221,15 | |
$480,18 | |
$5,93 | |
$224,51 | |
343,29K | |
-- | |
39,75 | |
$225,80 | |
$135,39 | |
-- | |
-- |
Biogen Inc. (BIIB) last closed at $224,51 as of 2026-09-04 23:34:00, unchanged from the previous close of $224,51.
During the latest regular trading session, BIIB traded between $5,93 and $480,18, with a volume of 343,29K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, Biogen Inc. (BIIB) moved from $216,47 to $220,88, representing a gain of 2,04% ($4,41).
The stock traded between $219,99 and $225,17 during the period. The latest price is near the lower end of the 7-day range, indicating moderate upward.
The average daily volume was 702,19 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 94,6%
BIIB is currently trading at $220,88, placing it 94,6% of the way from its 52-week low of $135,39 to its 52-week high of $225,80. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 7500 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Biogen Inc. (BIIB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.